High "on Treatment" Platelet Reactivity in the Intensive Care Unit

Critical Illness Clinical Trial

Official title:

High "on Treatment" Platelet Reactivity in the Intensive Care Unit

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02285751
• Other study ID #: HTPR-ICU
• Secondary ID: 2012-002226-76
• Status: Recruiting
• Phase: Phase 2
• Start date: November 2012
• Est. completion date: August 2020

Study information

• Verified date: August 2019
• Source: Medical University of Vienna
• Contact: Bernd Jilma, Ao. Univ.-Prof. Dr. med.
• Phone: 0043140400
• Email: bernd.jilma[@]meduniwien.ac.at
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

High "on treatment" platelet reactivity is defined as a poor pharmacodynamic response to the administration of acetylsalicylic acid or clopidogrel. acetylsalicylic acid and clopidogrel are drugs commonly used to reduce platelet activity and prevent cardiovascular events. High "on treatment" platelet reactivity is associated with a higher cardiovascular event rate.

Ticagrelor and prasugrel, like clopidogrel both P2Y12 inhibitors are effective in treating patients with High "on treatment" platelet reactivity to clopidogrel.

Critically ill patients are a unique population with altered pharmacokinetic and pharmacodynamic properties. Gastrointestinal dysmotility with associated altered resorption and impaired microvascular function occur frequently in critically ill patients and may lead to altered resorption of orally administered drugs.

The investigators will test a minimum of 100 patients treated with 100mg acetylsalicylic acid per os and 100 patients treated with 75mg clopidogrel per os to calculate the prevalence of high "on treatment" platelet reactivity.

30 patients with high "on treatment" platelet reactivity to acetylsalicylic acid will be randomized to three new treatment groups. In the first group patients will receive 200mg acetylsalicylic acid per os, in the second group 100mg acetylsalicylic acid intravenously and in the third group 81mg chewable acetylsalicylic acid. Each group will contain 10 patients. Pharmacokinetics and pharmacodynamics will be reassessed to evaluate the new treatment.

36 patients with high "on treatment" platelet reactivity to clopidogrel will be randomized to receive either an additional loading dose of 600mg clopidogrel (n=24) or to continue normal treatment as a control group (n=12). Pharmacokinetics and pharmacodynamics will be reassessed and those patients, who are tested again to have high "on treatment" platelet reactivity in spite of the additional loading dose, will now be randomized to receive either ticagrelor or prasugrel. The investigators expect about six patients per group. The twelve patients in the control group will continue normal treatment (75mg/day) until the end of the study. Pharmacokinetics and pharmacodynamics of ticagrelor and prasugrel will be assessed. Any patient, who is tested again with high "on treatment" platelet reactivity in spite of receiving prasugrel or ticagrelor, will be finally switched to the opposite drug and a final high "on treatment" platelet reactivity testing will be conducted.

16 patients who are treated with 10mg prasugrel per os will be tested for HTPR and if positively tested will be switched to 2x90mg ticagrelor per os per day. Platelet reactivity will be reassessed to test whether switching the medication benefits the patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: August 2020
• Est. primary completion date: July 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• >18years of age

• admittance to an intensive care unit

Exclusion Criteria:

• recent surgery

• active bleeding

• known coagulation disorders

• discretion of the physician

• terminal illness (anticipated life expectancy < 3months; e.g. due to cancer)

• pregnancy

• <20000 platelets

Related Conditions & MeSH terms

• Critical Illness

Intervention

Drug:
• acetylsalicylic acid

• clopidogrel

• prasugrel

• ticagrelor

Locations

Country	Name	City	State
Austria	General Hospital	Vienna

Sponsors (1)

Lead Sponsor	Collaborator
Medical University of Vienna

Country where clinical trial is conducted

Austria, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	pharmacodynamics (Arachidonic acid induced aggregation test with multiplate electrode aggregometry)	Arachidonic acid induced aggregation test with multiplate electrode aggregometry of patients with high "on treatment" platelet reactivity to acetylsalicylic acid after receiving new treatments as explained.; adenosine diphosphate induced aggregation tested with multiplate electrode aggregometry of patients with high "on treatment" platelet reactivity to clopidogrel after an additional loading dose clopidogrel, or after receiving prasugrel or ticagrelor	on average 3 days
Secondary	Prevalence of high "on-treatment" platelet reactivity in the intensive care unit	percentage of patients tested with high "on treatment" platelet reactivity according to defined values	maximum 2 weeks after admission
Secondary	Evaluation of pharmacokinetics (Serum levels of Salicylate/acetylsalicylic acid, clopidogrel-active metabolite, prasugrel-active metabolite, ticagrelor active-metabolite)	Serum levels of Salicylate/acetylsalicylic acid, clopidogrel-active metabolite, prasugrel-active metabolite, ticagrelor active-metabolite	on average 3 days
Secondary	intensive care unit mortality	discharge of ICU	maximum 90 days
Secondary	comparison of hemodynamically stable vs unstable ((defined by serum lactate>2.1mmol/l, need for circulatory support)	hemodynamically stable vs unstable (defined by serum lactate>2.1mmol/l, need for circulatory support)	maximum 3 days
Secondary	major bleeding (defined by TIMI-TRITON-38 criteria)	assessment of major bleeding incidences defined by TIMI-TRITON-38 criteria	average of 2 weeks within inclusion